



September 14, 2021

Company name: SanBio Co., Ltd.  
Representative: Keita Mori, Representative Director and  
President  
(TSE Mothers Code: 4592)  
Contact: Yoshihiro Kakutani, Corporate Officer of  
Management Administration  
(TEL. +81-3-6264-3481)

**Notice Concerning Difference Between Consolidated Financial Forecasts and Actual Results  
for the First Half of the Fiscal Year Ending January 31, 2022**

SanBio Company Limited (hereafter, “the Company”) hereby announces the difference between consolidated financial forecasts disclosed on March 17, 2021 and the actual results disclosed today, for the first half of the fiscal year ending January 31, 2022 (from February 1, 2021 to July 31, 2021).

1. Difference between consolidated forecasts and actual results for the first half of the fiscal year ending January 31, 2022 (from February 1, 2021 to July 31, 2021)

	Operating Revenue	Operating Income	Ordinary Income	Net Income Attributable to Owners of Parent	Net Income Per Share
Previous Forecast (A) (as of March 17, 2021)	Million yen —	Million yen -3,492	Million yen -3,550	Million yen -3,551	Yen -68.57
Actual Results (B)	—	-3,052	-2,146	-2,134	-41.21
Difference (B-A)	—	440	1,404	1,417	
Percentage Change (%)	—	—	—	—	
(Reference) Actual results for the six months ended July 31, 2020)	—	-2,570	-3,205	-3,207	-61.94

2. Reasons for the difference

The operating loss was as noted above, as R&D and manufacturing expenses expected to be recognized in the first half of the fiscal year now will be booked in the second half. The ordinary loss and net loss attributable to owners of parent were as noted above, as the Company booked a foreign exchange gain due to the depreciation of the yen.

Consolidated forecasts for the full year ending January 31, 2022 are unchanged from those released on March 17, 2021.